文献速递皮肤肿瘤

美国Medicare人群皮肤活检与皮肤癌治疗操作的生态学研究(2000-2015)

An ecological study of skin biopsies and skin cancer treatment procedures in the United States Medicare population, 2000 to 2015.
PubMed 文献 · J Am Acad Dermatol · 2017-09-22

该生态学研究分析2000至2015年Medicare理赔数据,描述皮肤活检与皮肤癌相关操作的趋势。结果显示活检增加142%,皮肤癌操作增加56%;校正Medicare参保人数增长(+36%)后,每1000名受益人活检数从56增至99,Mohs显微描记手术从5增至15,而切除和破坏操作变化极小。

要点

  • 活检总数增加142%,皮肤癌操作总数增加56%,但校正参保人数增长后切除和破坏操作变化极小。
  • 每1000名受益人活检数从56增至99,Mohs显微描记手术从5增至15。
  • Mohs显微描记手术在头颈、手足和生殖器部位占比从11%升至27%,在躯干四肢从1%升至4%。

核心结论

  • 皮肤癌操作数量的增加在很大程度上归因于Medicare人群随时间增长。
  • Mohs显微描记手术使用增加主要在高、中风险及功能和美学重要部位。

研究设计与样本

  • 生态学研究,分析2000至2015年Medicare受益人皮肤活检和皮肤癌操作的理赔数据。

主要发现

  • 活检增加142%,皮肤癌操作增加56%。
  • Mohs显微描记手术在头颈、手足和生殖器部位占比从11%升至27%,在躯干四肢从1%升至4%。
  • 校正Medicare参保人数增长(+36%)后,每1000名受益人活检数从56增至99,Mohs显微描记手术从5增至15,切除从18降至16,破坏从19降至18。
  • 每1000名受益人活检年增长量:2000-2007年4.3次,2008-2011年2.2次,2012-2015年0.5次。
  • 每1000名受益人Mohs手术年增长量:2000-2007年0.9次,2008-2011年0.5次,2012-2015年0.3次。

临床怎么用

  • 解读皮肤癌操作趋势时需考虑Medicare人群增长的影响。
  • Mohs显微描记手术的增加集中在高、中风险及功能和美学重要部位。

局限性

  • Medicare理赔数据不提供患者层面信息或非手术治疗信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Analyses of skin cancer procedures adjusted for population changes are needed. OBJECTIVE: To describe trends in skin cancer-related biopsies and procedures in Medicare beneficiaries. METHODS: An ecological study of Medicare claims for skin biopsies and skin cancer procedures in 2000 to 2015. RESULTS: Biopsies increased 142%, and skin cancer procedures increased 56%. Mohs micrographic surgery (MMS) utilization increased on the head/neck, hands/feet, and genitalia (increasing from 11% to 27% of all treatment procedures) but was low on the trunk/extremities (increasing from 1% to 4%). Adjusted for increased Medicare enrollment (+36%) between 2000 and 2015, the number of biopsies and MMS procedures performed per 1000 beneficiaries increased (from 56 to 99 and from 5 to 15, respectively), whereas the number of excisions and destructions changed minimally (from 18 to 16 and from 19 to 18, respectively). Growth in biopsies and MMS procedures slowed between each time period studied: 4.3 additional biopsies per year and 0.9 additional MMS procedures per year per 1000 beneficiaries between 2000 and 2007, 2.2 and 0.5 more between 2008 and 2011, and 0.5 and 0.3 more between 2012 and 2015, respectively. LIMITATIONS: Medicare claims-level data do not provide patient-level or nonsurgical treatment information. CONCLUSIONS: The increased number of skin cancer procedures performed was largely the result of Medicare population growth over time. MMS utilization increased primarily on high- and medium-risk and functionally and cosmetically significant locations where tissue sparing and maximizing cure are critical.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Wang DM, Morgan FC, Besaw RJ, et al. An ecological study of skin biopsies and skin cancer treatment procedures in the United States Medicare population, 2000 to 2015. J Am Acad Dermatol. 2017. PMID: 28947293. doi:10.1016/j.jaad.2017.09.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。